Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...
The CHMP decision follows a similar verdict on Eisai and Biogen's first amyloid-targeting drug Aduhelm (aducanumab), which was approved in the US on a fairly controversial dataset, but later ...
Aducanumab – which Biogen is developing with Japanese drugmaker Eisai – was all but abandoned in 2019 after the partners decided that two phase 3 trials of the drug were unlikely to show an ...
Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...
In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...
Biogen Pharmachem Industries Ltd share price was down by -0.86% from the previous closing price of ₹1.16. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...
Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...
The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...
A US university has launched a prevention trial examining the use of Eli Lilly’s investigational remternetug in young adults to prevent further development of Alzheimer’s disease. Washington ...
After hours: 7:30:46 p.m. EST ...